Home > Products > Featured products

Colivelin

  Cat. No.:  DC45278   Featured
Chemical Structure
867021-83-8
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Colivelin is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro. Colivelin exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease. Colivelin has the potential for the treatment of alzheimer's disease and ischemic brain injury
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 867021-83-8
Chemical Name: Colivelin
Synonyms: L-Proline,L-seryl-L-alanyl-L-leucyl-L-leucyl-L-arginyl-L-seryl-L-isoleucyl-L-prolyl-L-alanyl-L-prolyl-L-alanylglycyl-L-alanyl-L-seryl-L-arginyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-threonylglycyl-L-a-glutamyl-L-isoleucyl-L-a-aspartyl-L-leucyl-;Colivelin;L-Proline,L-seryl-L-alanyl-L-leucyl-L-leucyl-L-arginyl-L-seryl-L-isoleucyl-L-prolyl-L-alanyl-L...;L-Proline,L-seryl-L-alanyl-L-leucyl-L-leucyl-L-arginyl-L-seryl-L-isoleucyl-L-prolyl-L-alanyl-L-prolyl-L-alanylglycyl-L-alanyl;L-Proline,L-seryl-L-alanyl-L-leucyl-L-leucyl-L-arginyl-L-seryl-L-isoleucyl-L-prolyl-L-alanyl-L-prolyl-L-alanylglycyl-L-alanyl-L-seryl-L-arginyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-threonylglycyl-L-a;SER-ALA-LEU-LEU-ARG-SER-ILE-PRO-ALA-PRO-ALA-GLY-ALA-SER-ARG-LEU-LEU-LEU-LEU-THR-GLY-GLU-ILE-ASP-LEU-PRO;H-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro-OH;Remacemide hydrochloride;Colivelin TFA;s9664
SMILES: O=C([C@]([H])([C@@]([H])(C([H])([H])[H])C([H])([H])C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])O[H])N([H])C([C@]([H])(C([H])([H])C([H])([H])C([H])([H])N([H])/C(=N/[H])/N([H])[H])N([H])C([C@]([H])(C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])O[H])N([H])[H])=O)=O)=O)=O)=O)=O)N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(N([H])[C@@]([H])(C([H])([H])[H])C(N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(N([H])[C@]([H])(C(N([H])C([H])([H])C(N([H])[C@]([H])(C(N([H])[C@@]([H])(C([H])([H])O[H])C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])C([H])([H])C(N([H])[C@@]([H])(C([H])([H])C([H])([H])C(=O)O[H])C(N([H])[C@]([H])(C(N([H])[C@@]([H])(C([H])([H])C(=O)O[H])C(N([H])[C@@]([H])(C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])C(N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(=O)O[H])=O)=O)=O)[C@@]([H])(C([H])([H])[H])C([H])([H])C([H])([H])[H])=O)=O)=O)[C@@]([H])(C([H])([H])[H])O[H])=O)C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])=O)C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])=O)C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])=O)C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])=O)C([H])([H])C([H])([H])C([H])([H])N([H])/C(=N/[H])/N([H])[H])=O)=O)C([H])([H])[H])=O)=O)C([H])([H])[H])=O)=O)=O
Formula: C119H206N32O35
M.Wt: 2645.1024
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: Colivelin is a neuroprotective peptide and activator of STAT3.
Target: STAT3 Amyloid-β
In Vivo: Colivelin (intracerebroventricular administration; 10 pmol/3 μl; 3 weeks) suppresses impairment in spatial working memory induced by repetitive intracerebroventricular injection of Aβ25-35 or Aβ1-42, in addition, it antagonizes neuronal loss in the CA1 region of hippocampus induced by hippocampal injection of Aβ1-42[1]. Colivelin (intraperitoneal administration; 1.4, 7, or 35 nM/0.21 mL; on the Y-maze testday) suppresses memory impairment caused by 3-quinuclidinyl benzilateand restricts functional memory deficit[1]. Colivelin (intraperitoneal injection; 1 mg/kg; 14 days) results in improved motor and cognitive function with time by performance of mNSS, rotarod, and corner turning test.It also reduces lesion volume and improves neurological deficits after MCAO[3]. Animal Model: CD-1 mice[1] Dosage: 10 pmol/3 μl Administration: Intracerebroventricular administration Result: Completely suppressed Aβ 25-35-mediated impairment in spatial working memory and increased the number of immunoreactive neurons. Animal Model: C57 mice[1] Dosage: 1.4, 7, or 35 nM/0.21mL Administration: Intraperitoneal administration Result: Protected against cholinotoxin-induced amnesia in mice. Animal Model: Male C57BL/6 mice[3] Dosage: 1 mg/kg Administration: Intraperitoneal administration Result: Protected against ischemic brain injury, and improves neurological outcomes
In Vitro: Colivelin completely suppresses death induced by overexpressed FAD-causative genes and Aβ1-43 at a concentration of 100 fm, and keep its neuroprotective action at or above the levels of 1 nm[1]. Colivelin-induced neuroprotection occurs via two neuroprotective pathways: one mediated by Ca2+/calmodulin-dependent protein kinase IV, triggered by ADNF, and one mediated by signal transducer and activator of transcription 3, triggered by HN[1]. Colivelin reverses caspase3, Bax and Bcl-2 expressions in HT22 cells medaited by rmMFG-E8 in the co-cultured cells under OGD condition[4]. Colivelin (50 µg/mL, 4 hours) significantly increases the p-STAT3 protein levels in BV-2 cells[4]. Western Blot Analysis[4] Cell Line: BV-2 cells. Concentration: 50 µg/mL. Incubation Time: 4 hours. Result: Increased p-STAT3 levels. Cell Viability Assay[5] Cell Line: KYSE70 and TE8 cells. Concentration: 0.5 μM. Incubation Time: 1 hour (followed by CYT-Rx20 treatment) Result: Sgnificantly suppressed the viability in KYSE70 and TE8 cells.
References: [1]. Chiba T, et al. Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo. J Neurosci. 2005 Nov 2;25(44):10252-61. [2]. Pan Z, et al. Upregulation of HSP72 attenuates tendon adhesion by regulating fibroblast proliferation and collagen production via blockade of the STAT3 signaling pathway.Cell Signal. 2020 Mar 18:109606. [3]. Zhao H, et al. Colivelin Rescues Ischemic Neuron and Axons Involving JAK/STAT3 Signaling Pathway.Neuroscience. 2019 Sep 15;416:198-206. [4]. Fang YY, et al. MFG-E8 alleviates oxygen-glucose deprivation-induced neuronal cell apoptosis by STAT3 regulating the selective polarization of microglia. Int J Neurosci. 2020 Mar 12:1-10. [5]. Chiu WC, et al. The Synthetic β-Nitrostyrene Derivative CYT-Rx20 Inhibits Esophageal Tumor Growth and Metastasis via PI3K/AKT and STAT3 Pathways. PLoS One. 2016 Nov 22;11(11):e0166453.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC45278 Colivelin Colivelin is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro. Colivelin exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease. Colivelin has the potential for the treatment of alzheimer's disease and ischemic brain injury
DC8726 FLLL31 FLLK31 is a potent and selective inhibitor of the STAT3 signaling pathway.
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia